The authors suggested that IL6 could be used as a predictive marker to determine the toxicity of certain breast cancer treatments and may be a precursor to full geriatric assessment, a strategy that is recommended in the field of geriatric oncology [43]. The gene discussed is IL6; the disease is breast carcinoma.